Evidence map›Paper›PMID 39354270›Full record

ArticleTranslational stroke research2025

SARS-CoV-2 Spike Protein Exacerbates Thromboembolic Cerebrovascular Complications in Humanized ACE2 Mouse Model.

Stan P Heath, Veronica C Hermanns, Maha Coucha, Mohammed Abdelsaid

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational stroke research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Stan P HeathDepartment of Biomedical Sciences, School of Medicine, Mercer University, Savannah, GA, USA.
Veronica C HermannsDepartment of Biomedical Sciences, School of Medicine, Mercer University, Savannah, GA, USA.
Maha CouchaDepartment of Pharmaceutical Sciences, School of Pharmacy, South University, Savannah, GA, USA.
Mohammed AbdelsaidDepartment of Biomedical Sciences, School of Medicine, Mercer University, Savannah, GA, USA. Abdelsaid_ma@mercer.edu.ORCID http://orcid.org/0000-0001-9846-6623

Funding

American Heart Association 23AIREA1045073 to MAAmerican Heart Association-American Stroke Association 23AIREA1045073
6 · The paper itself

Abstract

COVID-19 increases the risk for acute ischemic stroke, yet the molecular mechanisms are unclear and remain unresolved medical challenges. We hypothesize that the SARS-CoV-2 spike protein exacerbates stroke and cerebrovascular complications by increasing coagulation and decreasing fibrinolysis by disrupting the renin-angiotensin-aldosterone system (RAAS). A thromboembolic model was induced in humanized ACE2 knock-in mice after one week of SARS-CoV-2 spike protein injection. hACE2 mice were treated with Losartan, an angiotensin receptor (AT

Indexed as

Angiotensin-Converting Enzyme 2Cerebrovascular DisordersCOVID-19Spike Glycoprotein, CoronavirusThromboembolismAngiotensin II Type 1 Receptor BlockersAnimalsCerebrovascular CirculationDisease Models, AnimalHumansLosartanMaleMiceMice, TransgenicRenin-Angiotensin SystemSARS-CoV-2ACE2 protein, humanAce2 protein, mouseAngiotensin-Converting Enzyme 2Angiotensin II Type 1 Receptor BlockersLosartanSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID-19-induced Thromboembolic ComplicationsRAAS BalanceSARS-CoV-2 Spike ProteinVascular-contributes to Cognitive Impairments and Dementia

Identifiers

PMID39354270
PMCPMC11973837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.